Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation
Stuart Morton(University of Padua), Mario Strazzabosco(Smilow Cancer Hospital), Tommaso Stecca(Ca' Foncello Hospital), Annarosa Floreani(University of Padua), Simone Brivio(University of Milano-Bicocca), Massimiliano Cadamuro(University of Padua), Ruth Joplin(Queen Elizabeth Hospital Birmingham), Marta Vismara(University of Milano-Bicocca), Nicolò Bassi(University of Padua), Luca Fabris(University of Padua), Alberto Furlanetto(Ca' Foncello Hospital), Marco Massani(AULSS 2 Marca Trevigiana)
Cited by 61
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
|Nature Genetics|2013|398
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
|Journal of Hepatology|2016|344